NAGE Overview

Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.

Wall Street analysts forecast NAGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAGE is16.33 USD with a low forecast of 12.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Niagen Bioscience Inc revenue for the last quarter amounts to 33.84M USD, increased 16.19

Niagen Bioscience Inc. EPS for the last quarter amounts to 0.05 USD, decreased -44.44

Niagen Bioscience Inc (NAGE) has 117 emplpoyees as of March 10 2026.

Today NAGE has the market capitalization of 418.02M USD.